IGF-1 LR3: dosing evidence
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
IGF-1 LR3 is described in available materials as a once-daily subcutaneous injection. The figures below are a generalized reference drawn from protocols and community reports, not from controlled human clinical trials.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 20 mcg once daily, subcutaneous | Starting dose |
| Typical regimen | 20–50 mcg once daily | Increase if needed |
| Upper range | up to 100 mcg/day; ~4–6 week cycle, then off | Maximum in this schedule |